Akademik Veri Yönetim Sistemi
Pediatric Hematology and Oncology, cilt.12, sa.1, ss.19-28, 1995 (Scopus)
Thirty-six patients with Imerslund-Gräsbeck syndrome are presented. The mean ages at presentation and diagnosis were 4.7 ± 3.7 years and 7.2 ± 4.2 years, respectively. The mean hemoglobin level was 5.8 ± 2.2 g/dL, the mean cell volume was 104.9 ± 11.6 fL, the white blood cell count was 4479 ± 2022/mm3, and the serum vitamin B12 level was 96.9 ± 73 pg/mL. At diagnosis, 5 of the 36 patients, aged 5 to 16 years, had neurologic symptoms. All the patients had severe megaloblastic changes in bone marrow precursor cells. Proteinuria was detected in 78% of them. Patients with proteinuria had a younger age of onset (P < 0.0001) and diagnosis (P < 0.001) compared with those without proteinuria. In all patients, vitamin B12 excretion unbound to intrinsic factor after a flushing dose of vitamin B12 was lower than normal, and there was no appreciable correction in urinary vitamin B12 excretion after binding of intrinsic factor. The impairment of vitamin B12 absorption studies in Schilling tests; however, showed great variation among patients. Serum haptoglobin values were close to zero in all patients, indicating the presence of that intravascular hemolysis in Imerslund-Gräsbeck syndrome. Variations among patients in the age of presentation, degree of impairment of vitamin B12 absorption, and presence or absence of proteinuria suggest a heterogeneity in etiology of Imerslund-Gräsbeck syndrome at the molecular level. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.